An Open-Label, Multicenter, Single Arm Phase II Study of Oral GW572016 [lapatinib] as Single Agent Therapy in Subjects With Advanced or Metastatic Breast Cancer Who Have Progressed While Receiving HERCEPTIN-Containing Regimens.

Trial Profile

An Open-Label, Multicenter, Single Arm Phase II Study of Oral GW572016 [lapatinib] as Single Agent Therapy in Subjects With Advanced or Metastatic Breast Cancer Who Have Progressed While Receiving HERCEPTIN-Containing Regimens.

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Apr 2015

At a glance

  • Drugs Lapatinib (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 09 Jun 2009 Actual initiation date changed from 1 Jun 2003 to 1 Nov 2003 as reported by ClinicalTrials.gov.
    • 09 Jun 2009 Actual initiation date changed from 1 Jun 2003 to 1 Nov 2003 as reported by ClinicalTrials.gov.
    • 04 Apr 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top